BioSpace News Archive

Finalist patient entrepreneurs recognized for potential of innovations in multiple sclerosis (MS)

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the first quarter ended March 31, 2019 and provided a business update.

Divya Annamraju, Deputy Director of Strategy for Medical Devices Product Supply at Bayer, was honored as a Luminary by the Healthcare Businesswomen’s Association at its annual Woman of the Year event, Thursday, May 9, at the Marriott Marquis in New York.

BioSpecifics Technologies Corp. announced its financial results for the first quarter ended March 31, 2019 and provided a corporate update.

BioTime, Inc., a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant for 2019 of up to 9 million Israeli New Shekels from the Israel Innovation Authority.

Investigators from around the country presented hundreds of studies about kidney health and chronic kidney disease during the National Kidney Foundation’s 2019 Spring Clinical Meetings in Boston, May 8-12.

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC), a global provider of software and software-enabled services for the financial services and healthcare industries, today announced that Bill Stone, Chairman and Chief Executive Officer, will speak at the JP Morgan TMC Conference on Tuesday, May 14th, 2019 at the Westin Boston Waterfront, in Boston, MA at 9:20 am ET.

Navitus Health Solutions, a full pass-through pharmacy benefits company, released its 2018 drug trend report today stating that it continued to provide substantially lower costs for its clients in 2018, achieving an industry leading total net cost per member per month (PMPM) of $75.83 across its commercial business, which is 15% lower than the industry average of $88.97 PMPM.

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg, a generic version of Genentech’s Tarceva®

CareOne Executive Vice President Elizabeth Straus, has been recognized in NJBiz’s 2019 “Healthcare Heroes” competition - in the category of Healthcare Professional of the Year.